Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Among authors: hartung hp. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Interferons in relapsing remitting multiple sclerosis.
Freedman M, King J, Oger J, Sharief M, Hartung HP; PRISMS study investigators. Freedman M, et al. Among authors: hartung hp. Lancet. 2003 May 24;361(9371):1822-3; author reply 1823-4. doi: 10.1016/S0140-6736(03)13419-8. Lancet. 2003. PMID: 12781558 No abstract available.
Are statins a treatment option for multiple sclerosis?
Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Neuhaus O, et al. Among authors: hartung hp. Lancet Neurol. 2004 Jun;3(6):369-71. doi: 10.1016/S1474-4422(04)00770-7. Lancet Neurol. 2004. PMID: 15157852 Review.
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Frohman EM, et al. Among authors: hartung hp. Arch Neurol. 2005 Oct;62(10):1519-30. doi: 10.1001/archneur.62.10.1519. Arch Neurol. 2005. PMID: 16216934 Review.
Towards individualised multiple-sclerosis therapy.
Gold R, Hartung HP. Gold R, et al. Among authors: hartung hp. Lancet Neurol. 2005 Nov;4(11):693-4. doi: 10.1016/S1474-4422(05)70205-2. Lancet Neurol. 2005. PMID: 16239174 No abstract available.
1,122 results